Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health technology assessment in osteoporosis.
Hiligsmann M, Kanis JA, Compston J, Cooper C, Flamion B, Bergmann P, Body JJ, Boonen S, Bruyere O, Devogelaer JP, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY. Hiligsmann M, et al. Among authors: flamion b. Calcif Tissue Int. 2013 Jul;93(1):1-14. doi: 10.1007/s00223-013-9724-8. Epub 2013 Mar 21. Calcif Tissue Int. 2013. PMID: 23515633 Free PMC article. Review.
Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia.
Reginster JY, Cooper C, Rizzoli R, Kanis JA, Appelboom G, Bautmans I, Bischoff-Ferrari HA, Boers M, Brandi ML, Bruyère O, Cherubini A, Flamion B, Fielding RA, Gasparik AI, Van Loon L, McCloskey E, Mitlak BH, Pilotto A, Reiter-Niesert S, Rolland Y, Tsouderos Y, Visser M, Cruz-Jentoft AJ. Reginster JY, et al. Among authors: flamion b. Aging Clin Exp Res. 2016 Feb;28(1):47-58. doi: 10.1007/s40520-015-0517-y. Epub 2015 Dec 30. Aging Clin Exp Res. 2016. PMID: 26717937 Free PMC article. Review.
Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.
Reginster JY, Abadie E, Delmas P, Rizzoli R, Dere W, der Auwera P, Avouac B, Brandi ML, Daifotis A, Diez-Perez A, Calvo G, Johnell O, Kaufman JM, Kreutz G, Laslop A, Lekkerkerker F, Mitlak B, Nilsson P, Orloff J, Smillie M, Taylor A, Tsouderos Y, Ethgen D, Flamion B. Reginster JY, et al. Among authors: flamion b. Osteoporos Int. 2006 Jan;17(1):1-7. doi: 10.1007/s00198-005-1984-3. Epub 2005 Aug 10. Osteoporos Int. 2006. PMID: 16091835
How to define responders in osteoarthritis.
Cooper C, Adachi JD, Bardin T, Berenbaum F, Flamion B, Jonsson H, Kanis JA, Pelousse F, Lems WF, Pelletier JP, Martel-Pelletier J, Reiter S, Reginster JY, Rizzoli R, Bruyère O. Cooper C, et al. Among authors: flamion b. Curr Med Res Opin. 2013 Jun;29(6):719-29. doi: 10.1185/03007995.2013.792793. Epub 2013 Apr 17. Curr Med Res Opin. 2013. PMID: 23557069 Free PMC article. Review.
Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science.
Compston J, Reid DM, Boisdron J, Brandi ML, Burlet N, Cahall D, Delmas PD, Dere W, Devogelaer JP, Fitzpatrick LA, Flamion B, Goel N, Korte S, Laslop A, Mitlak B, Ormarsdottir S, Ringe J, Rizzoli R, Tsouderos Y, Van Staa T, Reginster JY; Group for the Respect of Ethics and Excellence in Science. Compston J, et al. Among authors: flamion b. Osteoporos Int. 2008 Sep;19(9):1247-50. doi: 10.1007/s00198-008-0670-7. Epub 2008 Jul 5. Osteoporos Int. 2008. PMID: 18604578 No abstract available.
Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.
Smolen JS, Boers M, Abadie EC, Breedveld FC, Emery P, Bardin T, Goel N, Ethgen DJ, Avouac BP, Dere WH, Durez P, Matucci-Cerinic M, Flamion B, Laslop A, Lekkerkerker FJ, Miossec P, Mitlak BH, Ormarsdóttir S, Paolozzi L, Rao R, Reiter S, Tsouderos Y, Reginster JY; Group for Respect of Ethics and Excellence in Science (GREES). Smolen JS, et al. Among authors: flamion b. Curr Med Res Opin. 2011 Feb;27(2):315-25. doi: 10.1185/03007995.2010.542135. Epub 2010 Dec 9. Curr Med Res Opin. 2011. PMID: 21142618
Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.
Smolen JS, Boers M, Abadie EC, Breedveld FC, Emery P, Bardin T, Goel N, Ethgen DJ, Avouac BP, Durez P, Flamion B, Laslop A, Miossec P, Reiter S, Reginster JY; Task Force of the Group for the Respect of Ethics and Excellence in Science. Smolen JS, et al. Among authors: flamion b. Rheumatology (Oxford). 2011 Oct;50(10):1732-6. doi: 10.1093/rheumatology/keq413. Epub 2011 Jan 17. Rheumatology (Oxford). 2011. PMID: 21242246 No abstract available.
Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.
Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F, Reiter S, Laslop A, Breedveld F, Abadie E, Flamion B, Dere W, Mpofu S, Goel N, Ethgen D, Mitlak B, Ormarsdóttir S, Rao R, Tsouderos Y, Reginster JY; Group for Respect of Ethics and Excellence in Science (GREES). Miossec P, et al. Among authors: flamion b. Ann Rheum Dis. 2011 Oct;70(10):1713-8. doi: 10.1136/ard.2011.154252. Epub 2011 Jul 22. Ann Rheum Dis. 2011. PMID: 21784723 Free article. Review.
76 results